Profile
Sector:
HealthcareCountry:
CanadaIPO:
08 June 2018Website:
http://www.fsdpharma.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 16 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
HUGE Latest News
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system.
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings wit.
What type of business is FSD Pharma?
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.
What sector is FSD Pharma in?
FSD Pharma is in the Healthcare sector
What industry is FSD Pharma in?
FSD Pharma is in the Drug Manufacturers - Specialty & Generic industry
What country is FSD Pharma from?
FSD Pharma is headquartered in Canada
When did FSD Pharma go public?
FSD Pharma initial public offering (IPO) was on 08 June 2018
What is FSD Pharma website?
https://www.fsdpharma.com
Is FSD Pharma in the S&P 500?
No, FSD Pharma is not included in the S&P 500 index
Is FSD Pharma in the NASDAQ 100?
No, FSD Pharma is not included in the NASDAQ 100 index
Is FSD Pharma in the Dow Jones?
No, FSD Pharma is not included in the Dow Jones index
When was FSD Pharma the previous earnings report?
No data
When does FSD Pharma earnings report?
The next expected earnings date for FSD Pharma is 14 November 2024